Biogen Inc. Share Price Today: Live Updates & Key Insights

Biogen Inc. share price today is $183.14, up -1.06%. The stock opened at $182.67 against the previous close of $183.41, with an intraday high of $183.48 and low of $181.

Biogen Inc. Share Price Chart

Biogen Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Biogen Inc. Share Price Performance

$183.14 -0.0106(-1.06%) BIIB at 23 Mar 2026 12:13 PM Drug Manufacturers - General
Lowest Today 181
Highest Today 183.48
Today’s Open 182.67
Prev. Close 183.41
52 Week High 202.41
52 Week Low 110.04
Day’s Range: Low 181 High 183.48
52-Week Range: Low 110.04 High 202.41
1 day return -
1 Week return -0.89
1 month return -7.5
3 month return +3.9
6 month return +29.13
1 year return +28.22
3 year return -30.47
5 year return -33.32
10 year return -

Biogen Inc. Institutional Holdings

Vanguard Group Inc 11.89

BlackRock Inc 10.06

PRIMECAP Management Company 10.06

FMR Inc 6.42

Vanguard PRIMECAP Inv 5.70

State Street Corp 4.99

Vanguard Total Stock Mkt Idx Inv 3.16

Geode Capital Management, LLC 2.86

Point72 Asset Management, L.P. 2.64

Vanguard 500 Index Investor 2.55

Wellington Management Company LLP 2.42

Vanguard Mid Cap Index Institutional 2.17

Vanguard Health Care Inv 1.99

Fidelity Contrafund 1.97

NORGES BANK 1.80

JPMorgan Chase & Co 1.73

Amvescap Plc. 1.65

Vanguard Capital Opportunity Inv 1.59

Morgan Stanley - Brokerage Accounts 1.53

iShares Core S&P 500 ETF 1.27

Fidelity 500 Index 1.27

State Street® SPDR® S&P 500® ETF 1.18

Boston Partners Global Investors, Inc 1.17

AQR Capital Management LLC 1.04

Northern Trust Corp 1.02

Legal & General Group PLC 0.99

UBS Asset Mgmt Americas Inc 0.98

Barclays PLC 0.93

Vanguard Value Index Inv 0.92

Vanguard PRIMECAP Core Inv 0.90

Deutsche Bank AG 0.84

Bank of America Corp 0.83

Strategic Advisers Fidelity US TtlStk 0.82

iShares Biotechnology ETF 0.75

State Street®HlthCrSelSectSPDR®ETF 0.74

Fidelity Contrafund Commingled Pl S 0.66

Invesco S&P 500® Equal Weight ETF 0.65

Vanguard Mid-Cap Value ETF 0.62

JHancock Disciplined Value Mid Cap I 0.58

Vanguard Institutional Index I 0.57

Biogen Inc. Market Status

Strong Buy: 13

Buy: 4

Hold: 20

Sell: 0

Strong Sell: 0

Biogen Inc. Fundamentals

Market Cap 26630.80 M

PB Ratio 1.4744

PE Ratio 20.8815

Enterprise Value 29678.48 M

Total Assets 29439.50 M

Volume 2214268

Biogen Inc. Company Financials

Annual Revenue FY25:9810600000 9810.6M, FY24:9675900000 9675.9M, FY23:9993300000 9993.3M, FY22:10173400000 10173.4M, FY21:10981700000 10981.7M

Annual Profit FY25:6913600000 6913.6M, FY24:9675900000 9675.9M, FY23:7507300000 7507.3M, FY22:7895100000 7895.1M, FY21:8872000000 8872.0M

Annual Net worth FY25:1293389000 1293.4M, FY24:1632200000 1632.2M, FY23:1461800000 1461.8M, FY22:3046900000 3046.9M, FY21:1556100000 1556.1M

Quarterly Revenue Q4/2025:2279300000 2279.3M, Q3/2025:2454800000 2454.8M, Q2/2025:2645500000 2645.5M, Q1/2025:2431000000 2431.0M, Q4/2024:2454700000 2454.7M

Quarterly Profit Q4/2025:1783000000 1783.0M, Q3/2025:1578200000 1578.2M, Q2/2025:1699300000 1699.3M, Q1/2025:1853100000 1853.1M, Q4/2024:2454700000 2454.7M

Quarterly Net worth Q4/2025:-48411000 -48.4M, Q3/2025:466500000 466.5M, Q2/2025:634800000 634.8M, Q1/2025:240500000 240.5M, Q4/2024:266800000 266.8M

About Biogen Inc. & investment objective

Company Information Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Organisation Drug Manufacturers - General

Employees 7500

Industry Drug Manufacturers - General

CEO Mr. Christopher A. Viehbacher

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Biogen Inc. FAQs

What is the share price of Biogen Inc. today?

The current share price of Biogen Inc. is $183.14.

Can I buy Biogen Inc. shares in India?

Yes, Indian investors can buy Biogen Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Biogen Inc. shares in India?

You can easily invest in Biogen Inc. shares from India by:

Can I buy fractional shares of Biogen Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Biogen Inc.?

Biogen Inc. has a market cap of $26630.80 M.

In which sector does Biogen Inc. belong?

Biogen Inc. operates in the Drug Manufacturers - General sector.

What documents are required to invest in Biogen Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Biogen Inc.?

The PE ratio of Biogen Inc. is 20.88 and the PB ratio is 1.47.